Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Plasma Fractionation Market is anticipated to expand from USD 26.81 Billion in 2025 to USD 39.01 Billion by 2031, reflecting a compound annual growth rate of 6.45%. This complex procedure involves isolating therapeutic protein elements, such as coagulation factors, immunoglobulins, and albumin, from human blood plasma. The fundamental catalyst for this market growth is the rising incidence of hemophilia, neurological ailments, and immunological disorders, coupled with an expanding elderly demographic that relies on advanced therapies derived from plasma. Additionally, heightened awareness and enhanced diagnostic tools for rare illnesses are substantially boosting the need for these vital medical treatments.

Data from the National Blood Centre reveals that Italy collected 919.7 tonnes of plasma in 2025, demonstrating a continuous rise in the availability of this raw material. Nevertheless, the heavy expenses tied to the complete plasma collection and fractionation cycle pose a major obstacle to worldwide market expansion. These high costs negatively affect the global affordability and availability of plasma-based medicines, creating a substantial hurdle to deeper market penetration.

Market Driver

A primary catalyst for the worldwide plasma fractionation market is the escalating need for immunoglobulins in multiple therapeutic fields. These proteins are vital for managing a variety of illnesses, such as specific neurological conditions, autoimmune diseases, and primary immunodeficiencies. This continuous demand is propelled by better diagnostic tools that enable the prompt detection of these ailments, combined with a broadening therapeutic environment that acknowledges the effectiveness of immunoglobulin treatments. To illustrate, CSL's 2025 Annual Report, released in August 2025, indicated that CSL Behring achieved $6.064 billion in immunoglobulin revenue for that year, marking a significant year-over-year growth. Such progress highlights the crucial function these plasma-based therapies serve in meeting critical medical demands around the world.

The ongoing enlargement of plasma collection networks serves as another major growth driver, as it is essential for guaranteeing a reliable and growing source of raw materials for the fractionation process. Establishing new collection sites and strategically upgrading current facilities directly boost plasma availability, which in turn facilitates the increased manufacturing of crucial plasma-derived medicines. As an example, Fierce Pharma reported in September 2025 that Kedrion Biopharma intends to channel more than $260 million into broadening its United States infrastructure by adding upwards of 40 new plasma collection facilities.

This dedication illustrates the sector's proactive strategy for enhancing supply chains. Additionally, the broader market draws considerable funding, highlighted by Octapharma's 2025 Annual Report from February 2026, noting that the enterprise invested in excess of €440 million throughout 2025 to fortify its product lineup and back upcoming expansion. Together, these initiatives enhance the industry's ability to fulfill the needs of patients globally.

Market Challenge

The steep expenses linked to the entire plasma collection and fractionation workflow constitute a major hurdle for the expansion of the Global Plasma Fractionation Market. These high costs directly dictate the ultimate retail price of plasma-derived medicines. As a result, the global affordability and availability of these critical treatments, such as immunoglobulins and albumin, remain restricted, especially within budget-constrained healthcare systems. This dynamic directly curtails the widespread market adoption of these life-saving products.

These elevated costs are largely driven by the massive infrastructure and specific operational demands built into the supply chain. To provide context, the Georgetown Blood and Plasma Research Group noted that the United States featured 1,247 plasma collection facilities in 2025. Operating and staffing this vast network, alongside the highly regulated, energy-demanding, and complex fractionation methods, lead to significant ongoing expenses. These economic pressures are ultimately transferred to the end product, creating exorbitant treatment prices that limit patient accessibility and obstruct market growth in multiple regions worldwide.

Market Trends

A prominent trend in the industry is the rise of innovative and highly specialized plasma-derived treatments, which broadens the applications of plasma fractionation well past conventional offerings. This progression entails creating fresh protein fractions or adapting current therapies to treat a wider array of intricate health conditions with precise mechanisms or improved effectiveness.

To address unfulfilled medical requirements and broaden their offerings, organizations are pouring more funds into research and development. For example, Octapharma's 2025 Annual Report, issued in February 2026, detailed a €117 million investment in research and development, emphasizing the sector's dedication to cultivating innovation and introducing advanced plasma-based therapeutics. This strategic emphasis establishes novel treatment classifications and widens the overall market scope.

Another key trend is the integration of sophisticated separation and purification technologies, which is fundamentally transforming the safety and productivity of plasma fractionation. These technical upgrades facilitate increased plasma protein yields, enhance the purity of the final goods, and have the potential to lower production expenses. Such breakthroughs are essential for improving manufacturing scalability and guaranteeing a steady supply of secure, premium plasma-derived medicines. As highlighted by Fierce Pharma in March 2026, CSL launched a $1.5 billion upgrade at its Kankakee plant to incorporate its Horizon 2 production method, an advanced technique created to extract larger volumes of immunoglobulin from a standard plasma batch. This financial commitment highlights the market's pursuit of technological excellence and streamlined processing.

Key Market Players

• Grifols S.A.
• Octapharma AG
• Intas Pharmaceuticals Ltd
• LFB S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• Biotest AG
• Kedrion S.p.A
• Bio Products Laboratory Ltd.
• Bharat Serums and Vaccines Limited

Report Scope

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Fractionation Market, By Product:

• Albumin
• Immunoglobulins
• Coagulation Factors
• Protease Inhibitors
• Others

Plasma Fractionation Market, By Application:

• Neurology
• Hematology
• Oncology
• Immunology
• Others

Plasma Fractionation Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.